Showing 3 results for Rheumatoid Arthritis
Khadije Golbahari, Seyyed Meysam Abtahi Froushani,
Volume 8, Issue 3 (12-2018)
Abstract
BBackground & Objectives: Nowadays, attention to natural products with therapeutic potential has been increased. This study was carried out to investigate the effect of Thymol on the animal model of Rheumatoid arthritis (RA).
Materials & Methods: RA was induced by injection of complete Freund's adjuvant into the footpad of Wistar rats. Then, rats were allocated in 3 groups: treated with Thymol (100 mg/kg-orally), treated with Prednisolone (100 mg/kg-orally) and un-treated group. All treatments were initiated at the 5th day after induction. The change in the dorso-plantar diameter of hands and legs of each rat were recorded every other day until 23 days after induction.
Results: The edema and swelling of the soles of the feet of RA rats that received Thymol or prednisolone, were significantly decreased in a similar manner compared to RA rat without treatment. The serum levels of nitric oxide and myeloperoxidase correlated with the proliferation of spleen lymphocytes and the levels of IL-1 and IL-6 production were significantly decreased in treatment groups compared to control group rats. The level of decrease in the level of serum nitric oxide was higher in the thymol group compared to the prednisolone-induced group. Conversely, prednisone caused more decrease in the levels of IL-1 and IL-6 cytokines compared to RA rats that received thymol.
Conclusion: Thymol may be considered as a useful strategy to control RA disease.
Mahsa Saffar, Hiva Alipanah, Mohammad Reza Ataollahi,
Volume 9, Issue 4 (11-2019)
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory and complex autoimmune disease. It affects mainly small joints (of the hands and feet) and has many systemic manifestations.
The study of biomarkers in rheumatology is important to understand the mechanism involved in some rheumatic diseases. Discovering new biomarkers with key roles in various stages of the disease remains as an important issue in RA patients. Biomarkers are important for diagnosis and prognosis, target therapy, and guiding the clinical and response treatment of all phases of RA. Biomarkers improve diagnosis by closing the serological gap, providing prognostic information that allows disease activity and progression to be monitored. Biomarkers can be correlated with a risk of developing RA and can predict bone erosions and disease progression. Therefore, there is a need for a sensitive biomarker for early diagnosis of the disease. Some biomarkers are not specific (Rheumatoid Factor IgM) and some are not widely used due to technical problems (Antiprenuclear factor). On the other hand, anti-cyclic citrullinated peptide (anti-CCP) in the serum of patients are more specific for these patients.This move from traditional approaches to use more specific biomarkers for patient stratification and targeted treatment should greatly improve patient care and reduce medical costs.
Poopak Mohaghegh, Mohammad Sadegh Ghasempuor, Azizallah Dehghan,
Volume 16, Issue 1 (1-2026)
Abstract
